Related Experiment Video
Updated: Aug 12, 2025

09:18
Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
Published on: September 7, 2021
2.9K
Defective proteostasis in Alzheimer's disease
Danielle Cozachenco1, Felipe C Ribeiro1, Sergio T Ferreira2
1Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Ageing Research Reviews
|January 24, 2023
Summary
Cellular protein balance, or proteostasis, is vital for brain function. Its defects drive Alzheimer's disease progression and memory loss, suggesting therapeutic targets for protein regulation.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Proteostasis, the regulation of cellular proteins, is essential for neuronal function, learning, and memory.
- Defective proteostasis is increasingly linked to neurodegenerative disorders, particularly Alzheimer's disease (AD).
- AD, the most common dementia in the elderly, is characterized by impaired cognitive functions.
Purpose of the Study:
- To review the molecular pathways of protein synthesis and degradation altered in Alzheimer's disease.
- To discuss the role of proteostasis deregulation in synapse dysfunction and memory impairment in AD.
- To explore potential pharmacological strategies for correcting proteostasis defects in AD.
Main Methods:
- Literature review of molecular pathways involved in protein homeostasis.
- Analysis of studies linking proteostasis to Alzheimer's disease pathogenesis.
- Discussion of therapeutic targets for protein synthesis and degradation.
Main Results:
- Proteostasis involves protein synthesis, folding, modification, and degradation, all disrupted in AD.
- Deregulation of these processes contributes significantly to synaptic dysfunction and memory deficits in AD.
- Specific molecular pathways governing protein turnover are altered in the AD brain.
Conclusions:
- Restoring proteostasis represents a promising therapeutic avenue for Alzheimer's disease.
- Targeting protein synthesis and degradation pathways may alleviate cognitive decline in AD patients.
- Further research into molecular mechanisms can guide the development of novel AD treatments.
Related Concept Videos
The Proteasome
938
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
938
Alzheimer's Disease: Overview
596
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
596
Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Treatment
237
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237
Regulated Protein Degradation
7.4K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.4K
Export of Misfolded Proteins out of the ER
3.7K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.7K

